The Case Western Reserve University School of Medicine received a 5-year $1.84 million grant to investigate the role of the LRG1 protein in colorectal cancer growth and develop a novel treatment option for patients with metastatic colorectal cancer.
The combination of adagrasib and cetuximab may show clinical activity and promising survival outcomes in patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer.